small molecule

REDEMPLO

PLOZASIRAN SODIUM

Loss of exclusivitySeptember 2038latest FDA-listed patent expiry

CompanyArrowhead Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand name	REDEMPLO
Active ingredient	PLOZASIRAN SODIUM
Strength	EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML)
Dosage form	SOLUTION
Route	SUBCUTANEOUS
Modality	Small molecule
FDA approval	November 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12365899	September 2038	substance, product
11214801	September 2038	substance, product
10597657	September 2038	substance, product
10294474	March 2037	substance, product
11174481	March 2037	substance, product

Regulatory exclusivity

Code	Expires
ODE-541	November 2032

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.